Tramadol Hydrochloride Extended-release

36,700 adverse event reports submitted to the FDA (1997–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Tramadol Hydrochloride Extended-release in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Tramadol Hydrochloride Extended-release adverse event reports by reporter sex
SexReports
Female19,359
Male12,639
Unknown89

By Age Group

View age group data as a table
Tramadol Hydrochloride Extended-release adverse event reports by reporter age group
Age groupReports
0-17666
18-342,320
35-495,023
50-644,814
65-743,495
75+3,036

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Tramadol Hydrochloride Extended-release. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Tramadol Hydrochloride Extended-release adverse event reports by reported outcome
OutcomeReports
Other Serious25,419
Hospitalization11,452
Death7,071
Life-Threatening3,679
Non-Serious3,593
Disability2,992

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Tramadol Hydrochloride Extended-release. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Tramadol Hydrochloride Extended-release adverse event reports by year
YearReports
19971
19991
2004115
2005129
200693
200750
2008124
2009229
2010566
2011492
2012930
2013669
2014630
2015991
20161,030
20171,555
20181,818
20192,295
20202,129
20212,971
20222,923
20239,949
20243,695
20252,801
2026 (partial)514

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Tramadol Hydrochloride Extended-release

In FDA adverse event reports that mention Tramadol Hydrochloride Extended-release, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026